群英荟萃，智慧闪耀。肿瘤领域年度盛会2025美国临床肿瘤学会（ASCO 2025）年会即将于2025年5月30日~6月3日在美国芝加哥举行。近日，ASCO官网公布了摘要题目及讲者信息。【肿瘤资讯】特别整理口头摘要专场（Oral Abstract Session）和口头摘要速递专场（Rapid Oral Abstract Session）的黑色素瘤领域研究，与读者分享。
口头摘要专场
摘要号：LBA9507
英文标题：A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013).
中文标题：一项关于Encorafenib联合Binimetinib联合纳武利尤单抗对比伊匹木单抗联合纳武利尤单抗治疗 BRAF V600 突变型黑色素瘤脑转移患者的随机对照II期临床研究：SWOG S2000 (NCT04511013)
讲者：Zeynep Eroglu，H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
摘要号：LBA9501
英文标题：Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation.
中文标题：EORTC-2139-MG/Columbus-AD 试验的主要分析：一项关于 Encorafenib 和 Binimetinib 辅助治疗对比安慰剂用于治疗携带 BRAF-V600E/K 突变的高风险II期黑色素瘤患者的随机试验
讲者：Alexander van Akkooi，Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
摘要号：LBA9500
英文标题：Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
中文标题：比较纳武利尤单抗联合瑞拉利单抗与纳武利尤单抗单药对完全切除的 III–IV 期黑色素瘤进行辅助治疗：RELATIVITY-098 研究的主要结果
讲者：Georgina Long，Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, NSW, Australia
摘要号：LBA9505
英文标题：A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.
中文标题：一项评估新辅助帕博利珠单抗 (P) 单药对比联合 Vidutolimod (V) 方案用于高风险可切除黑色素瘤患者的 II 期随机研究：ECOG-ACRIN EA6194
讲者：Ahmad Tarhini，H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
摘要号：LBA9504
英文标题：Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis.
中文标题：一项关于新辅助抗PD-1药物Dostarlimab (D) 对比 D联合抗TIM-3药物Cobolimab (C) 治疗高危可切除黑色素瘤 (mel) 的随机II期研究 (NEO-MEL-T)：初步分析结果
讲者：Meghan Mooradian，Massachusetts General Hospital, Marblehead, MA
摘要号：LBA9506
英文标题：DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.
中文标题：DREAMseq：一项针对 BRAFV600 突变型转移性黑色素瘤患者治疗序列的 III 期临床试验 — 最终临床结果
讲者：Michael Atkins，Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
摘要号：LBA9502
英文标题：Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma.
中文标题：围手术期辅助帕博利珠单抗在临床IIB/C期黑色素瘤中的应用
讲者：John Miura，University of Pennsylvania, Media, PA
摘要号：LBA9503
英文标题：NeoACTIVATE arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage III melanoma.
中文标题：NeoACTIVATE C组：一项评估新辅助阿替利珠单抗联合Tiragolumab用于治疗高危可手术III期黑色素瘤患者的II期临床试验
讲者：Tina Hieken，Mayo Clinic, Rochester, MN
摘要号：LBA9508
英文标题：Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.
中文标题：比较抗PD-1免疫治疗1年疗程与至少2年疗程作为转移性黑色素瘤一线治疗的效果：DANTE III期试验结果
讲者：Sarah Danson，Cancer Therapeutics, Division of Clinical Medicine, University of Sheffield; Department of Oncology, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, United Kingdom
口头摘要速递专场
摘要号：9509
英文标题：A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
中文标题：一项在转移性葡萄膜黑色素瘤（MUM）及其他GNAQ/11突变型黑色素瘤患者中，评估DYP688（一种递送直接Gq/11抑制剂的抗体药物偶联物）的首次人体研究
讲者：Matteo Carlino，Sydney Medical School, Faculty of Medicine and Health Sciences, The University of Sydney, Camperdown and Melanoma Institute Australia, Sydney, and Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Westmead, NSW, Australia
摘要号：9510
英文标题：A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.
中文标题：一项评估白细胞介素-6 (IL-6) 受体阻断抗体Sarilumab (Sari) 联合伊匹木单抗(Ipi)、纳武利尤单抗(Nivo) 和Relatlimab (Rela) 治疗不可切除性III期或IV期黑色素瘤患者的II期研究
讲者：Janice Mehnert，Perlmutter Cancer Center of NYU Langone Health/NYU Grossman School of Medicine, New York, NY
摘要号：9513
英文标题：Single dose of neoadjuvant ipilimumab and nivolumab in resectable melanoma with CD8+ cell imaging: Interim results of the C-IT Neo trial.
中文标题：单次给药新辅助伊匹木单抗联合纳武利尤单抗治疗可切除黑色素瘤（联合CD8+细胞成像）：C-IT Neo试验的中期结果
讲者：Sarah Lochrin，Memorial Sloan Kettering Cancer Center, New York, NY
摘要号：9514
英文标题：A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
中文标题：一项关于新辅助仑伐替尼联合帕博利珠单抗治疗Merkel 细胞癌的II期研究
讲者：Andrew Brohl，H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
摘要号：9511
英文标题：Clinical outcomes of the DIET study: A randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB).
中文标题：DIET研究的临床结局：一项在接受免疫检查点阻断 (ICB) 治疗的黑色素瘤患者中，评估高纤维饮食干预 (HFDI) 效果的随机对照II期试验
讲者：Yufan Qiu，The University of Texas MD Anderson Cancer Center, Houston, TX
摘要号：9516
英文标题：Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM).
中文标题：利用输注产品特征预测转移性黑色素瘤（MM）患者对肿瘤浸润淋巴细胞（TIL）治疗的反应
讲者：Lilit Karapetyan，H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
摘要号：9517
英文标题：OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.
中文标题：Agni-01多中心研究I期结果：在免疫检查点抑制剂 (ICI) 耐药的晚期黑色素瘤患者 (pts) 中，评估表达可调控膜结合IL15 (mbIL15) 的OBX-115工程化肿瘤浸润淋巴细胞 (TIL) 细胞治疗
讲者：Jason Chesney，UofL Health – Brown Cancer Center, University of Louisville, Louisville, KY
摘要号：9515
英文标题：Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.
中文标题：Lifileucel在晚期黑色素瘤患者中的应用：C-144-01研究的5年结局
讲者：Theresa Medina，University of Colorado Comprehensive Cancer Center, Aurora, CO
摘要号：9512
英文标题：Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial.
中文标题：新辅助卡瑞利珠单抗联合阿帕替尼联合替莫唑胺治疗可切除II/III期肢端黑色素瘤：CAP 03-NEO试验
讲者：Lili Mao，Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China
排版编辑：肿瘤资讯-Kingsley
苏公网安备32059002004080号
